Oral Fluoroquinolones in the Treatment of Pneumonia, Bronchitis and Sinusitis
Authors:
Open Access
- 1 January 2002
- journal article
- research article
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 13 (5) , 293-300
Abstract
BACKGROUND: Despite a relatively large number of clinical studies comparing oral fluoroquinolones to one antibiotic class comparator, there is limited information on the relative efficacy of different fluoroquinolones.OBJECTIVE: To examine the efficacy and tolerability of oral fluoroquinolones in the treatment of mild to moderate community‐acquired pneumonia, acute exacerbations of chronic bronchitis and sinusitis.METHODS: A systematic review was undertaken with a MEDLINE search for antibiotics and indications. Included studies met the following criteria: original study; random allocation to treatment groups; treatment with one of the following oral antibiotics ‐ moxifloxacin, levofloxacin, ciprofloxacin, gatifloxacin; controlled by either placebo or an active comparator medication; double‐blind, single‐blind or open treatment; men and women (18 years of age and older); diagnosis of one of the three indications; and treatment duration of at least three days. Outcome measures included efficacy and safety. Comparative and single arm meta‐analyses were conducted. Statistical differences in antibiotic success rates were evaluated. Pooled point estimates and 95% CIs for the comparative statistics (z‐scores, P‐values) and the single‐arm analysis were examined to evaluate equivalence.RESULTS: The results of the comparative and single meta‐analyses revealed no major differences between the new fluoroquinolones. This is not surprising because the clinical studies were designed to show equivalence versus their comparators. Few comparative evaluations were conducted due to a paucity of studies. In relation to other competitors, small differences were seen.CONCLUSIONS: Results indicate that, in general, fluoroquinolones had similar efficacy, overall safety and dropout rates.Keywords
Funding Information
- Bayer Canada Inc.
This publication has 37 references indexed in Scilit:
- Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitisClinical Therapeutics, 2001
- Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitisClinical Therapeutics, 1999
- Randomized, Double‐Blind Study of Ciprofloxacin and Cefuroxime Axetil for Treatment of Acute Bacterial Exacerbations of Chronic BronchitisClinical Infectious Diseases, 1998
- Multicenter comparative trial of ciprofloxacin versus cefuroxime axetil in the treatment of acute rhinosinusitis in a primary care settingClinical Therapeutics, 1998
- Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg BID versus clarithromycin 500 mg BIDClinical Therapeutics, 1998
- Comparative Study of Efficacy and Safety of Ciprofloxacin and Cefixime in the Treatment of Acute Exacerbations of Chronic Bronchitis after First-Line Treatment FailureDrugs, 1995
- A prospective, double-blind, randomized study comparing the efficacy and safety of low-dose ciprofloxacin with ampicillin in the treatment of bronchitisDiagnostic Microbiology and Infectious Disease, 1990
- Community-Acquired Pneumonia Requiring Hospitalization: 5-Year Prospective StudyClinical Infectious Diseases, 1989
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986